General disorders and administration site conditions

There are 3 papers on general disorders and administration site conditions in aging research: 3 observational studies in people.

3 papers study it1 more mentions it1 finding

“females experiencing general disorders and administration site conditions”

Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroupsFrontiers in pharmacology2024doi:10.3389/fphar.2024.1463657

Humans3

Associations

1

Tirzepatide

upin humans1

1 study

Tirzepatide is associated with general disorders and administration site conditions in humans (sex-specific subgroup: females).
“females experiencing general disorders and administration site conditions”
Humanssex-specific subgroup: femalesfemales
Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups
Frontiers in pharmacologyNov 6, 2024

More on Tirzepatide

Latest

1 paper in 12 months

Frontiers in PharmacologySep 11

Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database

Study of 42,941 peoplePopulations

Frontiers in PharmacologyNov 6

Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups

Study of 37,827 peopleTirzepatide

Frontiers in PharmacologyDec 13

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS

Study in peoplePCSK9 inhibitors

Frontiers in PharmacologyJun 7

A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database

Study in peopleTirzepatide